Table 5 Change in marginal effects (percentage points) by discrete increases in the proportion of designated delivery sites
0%* | 1–10% | 11–20% | 31–30% | 31–40% | 41–50% | 51–60% | 61–70% | 71–80% | 81–90% | 91–100% | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Perinatal health | |||||||||||
Access to prenatal care | 0.581 | 0.582 (+ 0.001) | 0.583 (+ 0.002) | 0.584 (+ 0.002) | 0.585 (+ 0.003) | 0.586 (+ 0.004) | 0.586 (+ 0.005) | 0.587 (+ 0.006) | 0.588 (+ 0.007) | 0.589 (+ 0.007) | 0.590 (+ 0.008) |
Low birth weight | 0.096 | 0.096 (+ 0.000) | 0.095 (−0.001) | 0.095 (−0.001) | 0.094 (− 0.001) | 0.094 (− 0.002) | 0.094 (− 0.002) | 0.093 (− 0.003) | 0.093 (− 0.003) | 0.093 (− 0.003) | 0.092 (− 0.004) |
Preventive health screening & services | |||||||||||
Cervical cancer screening | 0.492 | 0.498 (+ 0.005) | 0.503 (+ 0.010) | 0.508 (+ 0.015) | 0.513 (+ 0.020) | 0.518 (+ 0.025) | 0.523 (+ 0.030)* | 0.528 (+ 0.035)* | 0.533 (+ 0.040)* | 0.538 (+ 0.045)* | 0.543 (+ 0.050)* |
Weight assessment & counseling (children) | 0.576 | 0.588 (+ 0.012) | 0.600 (+ 0.024) | 0.612 (+ 0.035)* | 0.623 (+ 0.047)* | 0.635 (+ 0.059)* | 0.647 (+ 0.071)* | 0.659 (+ 0.083)* | 0.671 (+ 0.095)* | 0.683 (+ 0.106)* | 0.694 (+ 0.118)* |
Weight assessment & counseling (adults) | 0.646 | 0.653 (+ 0.007) | 0.659 (+ 0.013) | 0.666 (+ 0.020) | 0.673 (+ 0.027) | 0.680 (+ 0.034)* | 0.686 (+ 0.040)* | 0.693 (+ 0.047)* | 0.700 (+ 0.054)* | 0.706 (+ 0.060)* | 0.713 (+ 0.067)* |
Colorectal cancer screening | 0.392 | 0.399 (+ 0.007) | 0.405 (+ 0.013) | 0.411 (+ 0.019) | 0.417 (+ 0.025) | 0.423 (+ 0.031)* | 0.430 (+ 0.038)* | 0.436 (+ 0.044)* | 0.443 (+ 0.051)* | 0.449 (+ 0.057)* | 0.456 (+ 0.064)* |
Childhood immunization status | 0.338 | 0.338 (+ 0.000) | 0.338 (+ 0.000) | 0.339 (+ 0.001) | 0.339 (+ 0.001) | 0.339 (+ 0.001) | 0.339 (+ 0.001) | 0.339 (+ 0.001) | 0.340 (+ 0.002) | 0.340 (+ 0.002) | 0.340 (+ 0.002) |
Chronic disease management | |||||||||||
Use of appropriate medications for asthma | 0.707 | 0.713 (+ 0.006) | 0.719 (+ 0.012) | 0.725 (+ 0.018) | 0.731 (+ 0.024) | 0.737 (+ 0.030) | 0.742 (+ 0.035)* | 0.748 (+ 0.041)* | 0.754 (+ 0.047)* | 0.759 (+ 0.052)* | 0.765 (+ 0.058)* |
Coronary artery disease: lipid therapy | 0.723 | 0.727 (+ 0.004) | 0.731 (+ 0.008) | 0.735 (+ 0.012) | 0.740 (+ 0.017) | 0.744 (+ 0.021) | 0.748 (+ 0.025)* | 0.752 (+ 0.029)* | 0.756 (+ 0.033)* | 0.760 (+ 0.037)* | 0.764 (+ 0.041)* |
IVD: use of aspirin or another antithrombotic | 0.740 | 0.745 (+ 0.005) | 0.750 (+ 0.010) | 0.755 (+ 0.015) | 0.759 (+ 0.019)* | 0.764 (+ 0.024)* | 0.769 (+ 0.029)* | 0.774 (+ 0.034)* | 0.778 (+ 0.038)* | 0.783 (+ 0.043)* | 0.788 (+ 0.048)* |
Controlling high blood pressure (hypertensive) | 0.598 | 0.602 (+ 0.004) | 0.605 (+ 0.007) | 0.609 (+ 0.011) | 0.613 (+ 0.015) | 0.616 (+ 0.018)* | 0.620 (+ 0.022)* | 0.624 (+ 0.026)* | 0.628 (+ 0.030)* | 0.631 (+ 0.033)* | 0.635 (+ 0.037)* |